BioCentury
ARTICLE | Distillery Therapeutics

Infectious disease

August 16, 2018 4:12 PM UTC

In vitro, cell culture, rat and dog studies identified a CYPA inhibitor that could help treat HCV. Chemical synthesis of analogs of the natural product sanglifehrin A and in vitro binding assays yielded a compound that bound CYPA with a Kd of 5 nM. In human hepatocyte-based replicon assays, the compound inhibited replication of an HCV genotype 2a strain with an EC50 of 98 nM. In rats and dogs, the compound had 100% and 55% oral bioavailability, and half-lives of 24 and 25 hours, respectively. Next steps by Gilead Sciences Inc. could include testing the compound in animal models of HCV...

BCIQ Company Profiles

Gilead Sciences Inc.

BCIQ Target Profiles

Cyclophilin A (CYPA) (PPIA)